Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at World Conference on Lung Cancer

PALOMA-2: Subcutaneous Amivantamab Administered Every 4 Weeks Plus Lazertinib in First-line EGFR -Mutated Advanced NSCLC

CARVYKTI_US-SR-10459

rybrevant dossier update - bottom

Lazcluze Dossier Update - bottom

Talvey Digital Dossier banner

CARVYKTI_US-SR-10545

Imaavy Dossier banner

Test-EL

Externally Sponsored Scientific Research

Submit your medical inquiry

Contact J&J Medical Connect for your medical inquiries


This page was last modified on

Additional contact #{index}

janssenscience

Congress Materials

Payer

Product Resources

rybrevant

Dark Blue

oncology

paloma-2-subcutaneous-amivantamab-video

Whitelist Modal

PALOMA-2: Subcutaneous Amivantamab Administered Every 4 Weeks Plus Lazertinib in First-line EGFR -Mutated Advanced NSCLC

Connect with us

Connect with us

Live video

Waiting for agent...

Ready to join